On the morning of my sister’s wedding, my father called me at 5:45 a.m.

The final presentation before the FDA drug evaluation committee took place in a sleek, windowless conference facility on the top floor of the federal health administration building in downtown Seattle. The room was cold, sterile, and dominated by a horseshoe-shaped oak table where five senior federal reviewers sat in severe, professional silence.

Clara stood at the head of the digital projection screen, dressed in a sharp charcoal blazer over a silk blouse, her silver necklace resting quietly against her collar. Beside her stood Leo, managing the slide deck and real-time data feeds.

Dr. Aris Thorne sat in the front row of the observer gallery, watching with quiet, unwavering confidence.

“Dr. Vance, your preliminary animal trial data is remarkably clean,” the lead federal reviewer, a stern-faced woman named Dr. Helen Vance—no relation—remarked, adjusting her glasses as she scanned the statistical models on her tablet. “However, the sheer speed at which your synthetic enzyme regenerates neural tissue is unprecedented. The committee needs absolute assurance that this intervention carries no latent oncological risks.”

Clara didn’t hesitate. She stepped forward, her voice calm, resonant, and entirely devoid of defensive hesitation.

“Dr. Vance, the risk of oncological mutation stems from uncontrolled cellular proliferation,” Clara explained, pulling up a detailed genetic sequencing slide on the screen behind her. “Our synthetic enzyme is engineered with a built-in biological self-destruct trigger—a programmed cellular half-life of exactly seventy-two hours. Once the damaged neural pathway is successfully bridged, the enzyme naturally degrades into harmless amino acids without triggering aberrant cell division.”